All In Biotech

NDA 211280 · Eli Lilly and CO

Reyvow

Lasmiditan Succinate · Oral

NovelDiscontinued

Last checked: Nov 20, 2026Latest source record: Sep 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 11, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

32

7 Phase 3, 1 recruiting

FAERS reports

1,163

206 serious, 13 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 8, 2026.

REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. REYVOW ® is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine. ( 1 ) Limitations of Use REYVOW is not indicated for the preventive treatment of migraine.

Mechanism: Lasmiditan binds with high affinity to the 5-HT 1F receptor. Lasmiditan presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT 1F receptor; however, the precise mechanism is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 11, 2019 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
3 products under this application
  • REYVOW · LASMIDITAN SUCCINATE EQ 100MG BASE · TABLET, ORAL · Discontinued
  • REYVOW · LASMIDITAN SUCCINATE EQ 200MG BASE · TABLET, ORAL · Discontinued
  • REYVOW · LASMIDITAN SUCCINATE EQ 50MG BASE · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Lasmiditan" as an intervention, any sponsor and status, largest first.

All 32 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness210
  • drug ineffective137
  • feeling abnormal118
  • somnolence109
  • migraine89
  • nausea86
  • sedation79
  • fatigue68
  • headache66
  • paraesthesia58
  • hallucination44
  • hypoaesthesia31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2020334
2021398
2022128
202383
202495
202575
202650

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Reyvow (Lasmiditan Succinate)

2024 spending

$9.8M

Beneficiaries

3,067

11,829 claims

Per beneficiary

$3,187

$91.20 per unit

View as table
YearSpending
2020$2,486,858
2021$5,806,062
2022$8,278,681
2023$9,927,259
2024$9,773,975

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 62 on PubMed

Sponsor: Eli Lilly

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.